Follicum AB announces that all patients have completed the treatment with FOL-005 in the Phase IIa study against hair loss.
Top-line data will be presented in the autumn. Follicum AB ("Follicum" or "The Company") today announces that all patients in the ongoing Phase IIa study with FOL-005 for hair loss have completed the treatment and finalized clinic visits. The Phase IIa study examines the safety and therapeutic effect of various doses of drug candidate FOL-005, administered as injections into the scalp.Follicum’s Phase IIa study is being conducted at the Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and at Bioskin, Hamburg, Germany. The study is blinded, and results will not be